Cargando…
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Autores principales: | Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446011/ https://www.ncbi.nlm.nih.gov/pubmed/34531405 http://dx.doi.org/10.1038/s41467-021-25901-z |
Ejemplares similares
-
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021) -
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023) -
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022) -
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020) -
Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition
por: He, Wei, et al.
Publicado: (2020)